NMC
MXCT icon

Nine Masts Capital’s MaxCyte MXCT Stock Holding History

Nine Masts Capital’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.7K Buy
+63,591
New +$59.4K 0.01% 157

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

Nine Masts Capital's MXCT Position: Q1 2026 in Review

Nine Masts Capital opened a new position in MaxCyte (MXCT) in Q1 2026: 63,591 shares worth $44.7K. The stake represents 0.01% of the portfolio and ranks #157 among its holdings.

130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Nine Masts Capital held 63,591 shares of MaxCyte worth $44.7K as of Q1 2026.
  • MaxCyte was a new Nine Masts Capital position in Q1 2026.
  • MaxCyte made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #157 holding.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.